Navigation Links
Yongye International Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Results
Date:3/15/2010

Yongye International, Inc., headquartered in Beijing, is engaged in the development, manufacturing, distribution and sales of Shengmingsu brand plant and animal nutrient products. The Company's patented and patent pending formulas and proprietary extraction processes allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Inner Mongolia Yongye Nongfeng Biotechnology Co., Ltd., is headquartered in Beijing with major operations located in Inner Mongolia, People's Republic of China. For more information, please visit the Company's website at http://www.yongyeintl.com .

    For more information, please contact:

    Yongye International, Inc.
     Mr. Larry Gilmore, VP Corporate Strategy
     Phone: +86-10-8232-8866 x8880
     Email: larry.gilmore@yongyeintl.com

    CCG Investor Relations
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com

     Mr. Athan Dounis, Account Manager
     Phone: +1-646-213-1916
     Email: 
SOURCE Yongye International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results
2. Yongye International Announces 2010-2012 Strategic Plan
3. Yongye International Announces Expansion of Research and Development Center
4. Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
5. Yongye Biotechnology International Receives License to Manufacture Products
6. Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance
7. Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day
8. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
9. Yongye Biotechnology Appoints New Chief Financial Officer
10. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
11. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... 28 , - Guests Will ... , Staying healthy in these stressful ... Attitude Health Retreats early in 2009 may provide,participants with the ... A key component of the retreat ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , ... it received a Staff Determination Letter (the "Letter") from ... the staff of Nasdaq,s Listing Qualifications Department determined, using ... the Company,s American Depository Shares ("ADRs") would be delisted ...
... web based CTMS (Clinical Trial Management System), has ... deployed visit reports, site payments, sponsor portal and ... project will include integration to our electronic data ... as other innovative functional changes to the system ...
Cached Biology Technology:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 3
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... in French . , A single ... is detrimental to the health of the arteries, while no ... fats such as mono-and polyunsaturated fatty acids, according to researchers ... Heart Institute. The Mediterranean meal may even have a positive ...
... up to 17,000 megatonnes of carbon dioxide into the ... by the CGIAR Research Program on Climate Change, Agriculture ... of food production needs to be reduced, a companion ... will require a complete recalibration of where specific crops ...
... to stand up and walk has come closer to reality ... never take another step. , A team of engineers at ... exoskeleton that enables people with severe spinal cord injuries to ... size and modular design promise to provide users with an ...
Cached Biology News:New study reveals that every single junk food meal damages your arteries 2Agriculture & food production contribute up to 29 percent of global greenhouse gas emissions 2Agriculture & food production contribute up to 29 percent of global greenhouse gas emissions 3Agriculture & food production contribute up to 29 percent of global greenhouse gas emissions 4An exoskeleton of advanced design promises a new degree of independence for people with paraplegia 2An exoskeleton of advanced design promises a new degree of independence for people with paraplegia 3An exoskeleton of advanced design promises a new degree of independence for people with paraplegia 4
muscle actin (HUC1-1)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
NATIVE RAT OSTEOCALCIN...
Biology Products: